Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure (SAFE-LAAC)

  • End date
    Jun 23, 2027
  • participants needed
  • sponsor
    Institute of Cardiology, Warsaw, Poland
Updated on 4 October 2022
antiplatelet agents
left atrial appendage closure
left atrial appendage occlusion
transesophageal echocardiography


SAFE-LAAC Trial has been designed to gather data on the most optimal strategy of antiplatelet therapy after transcatheter left atrial appendage occlusion with Amplatzer or WATCHMAN device



Transcatheter left atrial appendage closure (LAAC) has been shown to be non-inferior to oral anticoagulation in preventing cardioembolic strokes associated with atrial fibrillation. However, an optimal antithrombotic treatment regimen following successful LAAC remains an unresolved issue. The scope and duration of antiplatelet treatment following LAAC are of paramount importance as they may significantly contribute to post-procedural as well as long-term procedural safety and efficacy.


SAFE-LAAC Trial has been designed as a comparative health effectiveness study with the following aims:

  1. compare the safety and efficacy of 30 days vs. 6 months of dual antiplatelet therapy following LAAC with Amplatzer or WATCHMAN device (randomized comparison)
  2. compare safety and efficacy of stopping all antithrombotic and antiplatelet agents 6 months after LAAC vs. long-term treatment with a single antiplatelet agent (nonrandomized comparison)

Patient population:

Patients (n=200) after successful LAAC with Amplatzer or WATCHMAN device.


Results of this pilot trial will provide: 1. data to aid practitioners and guideline writers recommend the most optimal antithrombotic treatment after LAAC, and 2. data to support power calculations for designing future randomized trials.


SAFE LAAC has been designed as a multicenter (planned contribution of 7 centers in Poland), open-label, comparative health effectiveness trial with central, independent adjudication of events comprising the primary end-point. The first part of the trial is randomized and after 6 months of follow-up continues for another 12 months as a non-randomized study.


The duration of the trial has been planned for 5 years. The enrollment phase has been planned for 3 years.

Condition Atrial Fibrillation
Treatment short postimplantation dual antiplatelet therapy, extended postimplantation dual antiplatelet therapy, long-term treatment with a single antiplatelet agent, 6 months treatment with a single antiplatelet agent
Clinical Study IdentifierNCT03445949
SponsorInstitute of Cardiology, Warsaw, Poland
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Successful left atrial appendage occlusion with Amplatzer or WATCHMAN device within 37 days before randomization
Treatment with dual antiplatelet therapy (clopidogrel and acetylsalicylic acid) between left atrial appendage closure and randomization
Participant's age 18 years or older at the time of signing the informed consent form
Participant is willing to follow all study procedures; especially the randomized antiplatelet treatment regimen
Participant is willing to sign the study informed consent form

Exclusion Criteria

Indications to dual antiplatelet therapy other than atrial fibrillation and/or left atrial appendage occlusion at the time of enrollment or predicted appearance of such indications within the duration of the trial (e.g. planned coronary revascularization)
Indications to anticoagulation at the time of enrollment and/or predicted appearance of such indications within the duration of the trial (e.g. pulmonary embolism)
Known allergy to clopidogrel and/or acetylsalicylic acid precluding its administration as specified by the protocol
Any known inborn or acquired coagulation disorders
Peridevice leak >5mm on imaging study preceding enrollment
Left atrial thrombus on an imaging study performed after successful left atrial appendage closure but before enrollment
Life expectancy of fewer than 18 months
Participation in other clinical studies with experimental therapies at the time of enrollment and preceding 3 months
Chronic kidney disease stage IV and V
Women who are pregnant or breastfeeding; women of childbearing potential who do not consent to apply at least two methods of contraception. This criterion does not apply to women 2 years post menopause (with negative pregnancy test 24 hours prior to randomization if <55 years old) or after surgical sterilization
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note